EU/3/12/1059

About

On 8 November 2012, orphan designation (EU/3/12/1059) was granted by the European Commission to Nerviano Medical Science Srl, Italy, for milciclib maleate for the treatment of malignant thymoma.

The sponsorship was transferred to Tiziana Life Sciences PLC, United Kingdom, in November 2015.

Key facts

Active substance
milciclib maleate
Disease / condition
Treatment of malignant thymoma
Date of first decision
08/11/2012
Outcome
Positive
EU designation number
EU/3/12/1059

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Tiziana Life Sciences PLC
18 South Street
Mayfair
London W1K 1DG
United Kingdom
Tel. +44 (0)20 7493 2853
Fax +44 (0)20 7495 2379
E-mail: info@tizianalifesciences.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating